QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.105.090951v1 315/3/1380    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holland, P. R. Articles by Goadsby, P. J. Search for Related Content PubMed PubMed Citation Articles by Holland, P. R. Articles by Goadsby, P. J.

NEUROPHARMACOLOGY

Orexin 1 Receptor Activation Attenuates Neurogenic Dural Vasodilation in an Animal Model of Trigeminovascular Nociception

Headache Group, Institute of Neurology, London, United Kingdom

Received June 14, 2005; accepted September 8, 2005.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
The pathophysiology underlying the pulsating quality of the pain of a migraine attack is not fully understood, although trigeminal vascular afferents containing the sensory neuropeptide calcitonin gene-related peptide (CGRP) must have a role. Antimigraine drugs, such as triptans, serotonin 5-hydroxytryptamine_1B/1D receptor agonists, reproducibly block neurogenic vasodilation associated with CGRP release. We examined the effects of the hypothalamic neuropeptides orexin A and orexin B on neurogenic dural vasodilation, dissecting out the receptor pharmacology with the novel orexin 1 (OX₁) receptor antagonist N-(2-methyl-6-benzoxazolyl)-N''-1,5-naphthyridin-4-yl urea (SB-334867). Electrical stimulation of dural afferents (50–300 µA) resulted in reproducible dural vasodilation of 136 ± 9%. Orexin A 30 µg kg^–1, but not 3 and 10 µg kg^–1, inhibited the dilation brought about by electrical stimulation over 60 min and maximally after 15 min by 60% (t₇ = 7.138; P < 0.001; n = 8). This response was reversed by pretreatment with the OX₁ receptor antagonist SB-334867. Addition of CGRP_8-37 at the point of maximal effect of orexin A produced a further significant decrease in neurogenic dural vasodilation compared with orexin A only. CGRP administration (1 µg kg^–1) produced a reproducible dural blood vessel dilation of 145 ± 7% that was not inhibited by intravenous administration of orexin A (30 µg kg^–1). Orexin B had no significant effect even at the highest dose. The current study demonstrates that orexin A is able to inhibit neurogenic dural vasodilation via activation of the OX₁ receptor, resulting in inhibition of prejunctional release of CGRP from trigeminal neurons.

Trigeminal afferents innervating the cranial blood vessels contain the sensory neuropeptides calcitonin gene-related peptide (CGRP), substance P, and neurokinin A (Edvinsson and Goadsby, 1998). Williamson et al. (1997a) demonstrated that electrical stimulation of dura mater causes CGRP release from the prejunctional nerve fibers innervating the dural blood vessels, resulting in reproducible vasodilation. Blocking this vasodilation has proved to be an effective indicator of acute antimigraine efficacy, with many compounds, including the triptans (Williamson et al., 1997b,c) and CGRP antagonists (Williamson et al., 1997a), able to inhibit the vasodilation as well as provide effective antimigraine therapy (Ferrari et al., 2002; Olesen et al., 2004).

The orexins are two hypothalamic neuropeptides cleaved from the same 130 amino acid precursor peptide preproorexin, which is encoded by a single gene located on chromosome 17q21 in humans. After proteolytic cleavage, orexins A and B are post-translationally modified to form a 33- and 28-residue peptide, respectively, that share 46% homology (Sakurai et al., 1998; Sakurai, 2005). The orexins bind to two G protein-coupled receptors, termed OX₁ and OX₂. The two receptors are 64% homologous, and the rat and human receptors for OX₁ and OX₂ demonstrate 94 and 95% homology, respectively, suggesting a high level of conservation across mammalian species (Sakurai et al., 1998). Orexin A has equal affinity for the OX₁ and OX₂ receptors, with orexin B demonstrating a 10-fold higher affinity for the OX₂ receptor (Sakurai et al., 1998). Activation of either receptor results in elevated levels of intracellular Ca²⁺ concentrations, which results in the enhancement of the G_q-mediated stimulation of phospholipase C (Smart and Jerman, 2002).

Orexin fibers project throughout the nervous system, including dense projections to the locus coeruleus, dorsal raphe nucleus of the brainstem as well as less dense projections to the spinal cord dorsal and ventral horns, brainstem motor nuclei, periaqueductal gray, thalamus, and hypothalamus (Peyron et al., 1998; Cutler et al., 1999; van den Pol, 1999). Peripherally, orexin fibers and receptors have been localized to the pituitary, adrenal glands, gut, and testis (Blanco et al., 2001; Johren et al., 2001). The broad projections of the orexinergic system have led to its implication in a variety of functions, including feeding, sleep wake cycle, cardiovascular function, hormone secretion (Ferguson and Samson, 2003; Siegel, 2004; Sakurai, 2005; Samson et al., 2005) and more recently the modulation of nociceptive processing (Bingham et al., 2001; Cheng et al., 2003; Yamamoto et al., 2003; Kajiyama et al., 2005).

The hypothalamus is known to play an important role in the pathophysiology of cluster headache and the same may be true for migraine (Peres et al., 2001). The presence of premonitory symptoms up to 48 h preceding an attack (Giffin et al., 2003) combined with the circadian rhythmicity and link to hormonal fluctuations (Silberstein and de Lignieres, 2000) indicates a possible transient hypothalamic dysfunction. The orexinergic system projects to multiple neuronal systems (Peyron et al., 1998), which offers possible mechanisms by which the hypothalamus can influence nociceptive processing. Bartsch et al. (2004) demonstrated that microinjection of orexins A and B into the posterior hypothalamus had differential effects on the modulation of nociceptive meningeal and facial input to the trigeminal nucleus caudalis. Furthermore, destruction of the posterior hypothalamus in rats causes transient hyperalgesia (Millan et al., 1983), indicating a possible role in maintaining basal nociceptive threshold.

The purpose of this study was to identify the effect of varying doses of intravenous orexins A and B on neurogenic and CGRP-induced dural vasodilation and to dissect the receptor pharmacology of any response by using the novel OX₁ receptor antagonist SB-334867 and the CGRP receptor antagonist CGRP_8-37. The method uses dilation of dural blood vessels as a measure of trigeminal nerve activation; thus, compounds that can inhibit the vasodilatory response may have the potential to inhibit trigeminovascular nociceptive transmission.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Surgical Preparation
All experiments were conducted under the UK Home Office Animals (Scientific Procedures) Act (1986). Male Sprague-Dawley rats (280–350 g) were anesthetized throughout the experiments with 60 mg kg^–1 pentobarbital sodium salt intraperitoneally and then 10 mg kg^–1 intravenously as required (Sigma Chemical, Poole, Dorset, UK). The left femoral artery and vein were cannulated for blood pressure recording and intravenous infusion of anesthetic and test compounds, respectively. Temperature was maintained throughout by using a homoeothermic blanket system. The rats were placed in a stereotaxic frame and ventilated with oxygen-enriched air, 3 to 5 ml, 60 to 80 strokes per min (Small Rodent Ventilator model 683; Harvard Apparatus, Ltd., Edenbridge, Kent, UK). End-tidal CO₂ was monitored (Capstar-100; CWE Inc., Ardmore, PA) and kept between 3.5 and 4.5%, and blood pressure was monitored continually, allowing monitoring for changes in respiration and blood pressure due to anesthesia. The skull was exposed, and the right or left parietal bone was thinned by drilling with a saline-cooled drill until the blood vessels of the dura mater were clearly visible through the intact skull.

Intravital Microscopy
The cranial window was covered with mineral oil (37°C), and a branch of the middle meningeal artery was viewed using an intravital microscope (Microvision MV2100; Finlay Microvision, Warwickshire, UK), and the image was displayed on a television monitor. Dural blood vessel diameter was continuously measured using a video dimension analyzer (Living Systems Instrumentation, Burlington, VT) and displayed with blood pressure on an online data analysis system (CED spike2v5 software; CED, Cambridge, UK).

Experimental Protocols
Defining Electrical Stimulation Parameters. Electrical stimulation was used to evoke dilation of the dural blood vessels with a bipolar stimulating electrode (NE 200X; Clarke Electromedical Instruments, Pangbourne, UK) placed on the surface of the cranial window approximately 200 µm from the vessel of interest. The surface of the cranial window was stimulated at 5 Hz, 1 ms for 10 s (Grass Stimulator S88; Grass Instruments, Quincy, MA), with increasing voltage until maximal dilation was observed. Subsequent electrically induced responses in the same animal were then evoked using that voltage (Williamson et al., 1997a; Akerman et al., 2002). The reproducibility of this vasodilator response to electrical stimulation has been demonstrated previously using consecutive saline-controlled stimuli (Akerman et al., 2002).

Effect of Orexin on Evoked Dural Vessel Dilation. Two control responses to dural electrical stimulation were performed, and at least 10 min later, orexin A (n = 8) or B (n = 7), at doses of 3, 10, and 30 µg kg^{– 1} was administered intravenously. Electrical stimulation was then repeated 5, 15, 30, 45, and 60 min after the orexin treatment. For the antagonist studies, two control responses to dural electrical stimulation were performed and, at least 10 min later, SB-334867 was administered intravenously. This was followed by further electrical stimulation after 5 min and then followed by orexin A or B (n = 6) treatment, after which stimulation was repeated 5, 15, 30, 45, and 60 min later.

Effect of Orexin A and CGRP_8-37 on Evoked Dural Vessel Dilation. Two control responses to dural electrical stimulation were performed, and at least 10 min later, 30 µg kg^–1 orexin A was administered intravenously and then the electrical stimulation was repeated 5, 15, 30, 45, and 60 min after the orexin treatment. To investigate the effect of orexin A and CGRP_8-37, the CGRP_8-37 was administered intravenously immediately before the 15 min stimulation postorexin A (n = 6).

Effect of Orexin A on CGRP-Evoked Dural Vessel Dilation. Two control responses to CGRP-induced dilation were performed, and at least 10 min later 30 µg kg^–1, orexin A (n = 6) was administered intravenously and then the CGRP induced dilation was repeated 5, 15, 30, 45, and 60 min after the orexin treatment.

Data Analysis
The effects of electrical stimulation and CGRP administration on dural vessel diameter were calculated as a percentage increase from the prestimulation baseline diameters. The nature of the experimental setup, where the magnification of the dural vessel visualized was different in each animal by virtue of selecting an appropriate target vessel, made it impossible to standardize the dural vessel measurement; therefore, the change in dural vessel diameter is reported as a percentage change from baseline. The typical vessel diameter measured in the study ranged from 120 to 150 µm. All data are expressed as mean ± S.E.M. Statistical analysis was performed using an analysis of variance for repeated measures with Bonferroni post hoc correction for multiple comparisons followed by Student's paired t test. To compare the effect of orexin A only and orexin A and CGRP_8-37, an independent samples t test was used (SPSS version 12.0; SPSS Inc., Chicago, IL). Significance was assessed at the P < 0.05 level.

Drugs
The delivery of anesthetic and experimental drugs was via the same femoral catheter; however, the line was always flushed with saline first, several minutes before administering a different compound. Orexins A and B (Tocris Cookson Inc., Bristol, UK) were dissolved in water for injection at a maximum dose of 30 µg kg^–1. SB-334867, a kind donation from GlaxoSmithKline (Uxbridge, Middlesex, UK) was dissolved in 2-hydroxy--cyclodextrin (Sigma Chemical) with a few drops of dimethyl sulfoxide to aid solubility and injected at a dose of 10 mg kg^–1. CGRP (rat; Tocris Cookson Inc.) was initially dissolved in distilled water, aliquoted, and frozen. Subsequent dilutions were made in 0.9% saline before injection at a dose of 1 µg kg^–1. CGRP_8-37 (rat; Tocris Cookson Inc.) was dissolved in 0.9% saline for injection at a dose of 300 µg kg^–1. All drugs were made fresh on the morning of an experiment and administered in volumes ranging from 0.1 to 0.3 ml.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Effects of Orexin A on Neurogenic Dural Vasodilation. Electrical stimulation (50–300 µA) produced reproducible dural blood vessel dilation of 136 ± 9% (n = 35). Orexin A given intravenously at 3 and 10 µg kg^–1 did not significantly attenuate the response to electrical stimulation of the cranial window, but it had a significant effect at 30 µg kg^–1 (F_2.4,16.6 = 16.4; P < 0.001; Figs. 1 and 2; Table 1). Orexin A produced its maximum effect after 15 min, reducing the neurogenic dural vasodilation by 60% (t₇ = 7.1; P < 0.001; n = 8). Pretreatment with SB-334867, the selective OX₁ receptor antagonist 5 min before orexin A administration, blocked the observed reduction in neurogenic dural vasodilation (F_2.4,11.9 = 2.08; P = 0.16; Table 2), indicating that orexin A response was most likely mediated through the OX₁ receptor (Fig. 2). Orexin A or SB-334867 did not elicit any significant blood pressure changes, and SB-334867 demonstrated no effect on neurogenic vasodilation when given alone. The addition of CGRP_8-37, 13 min postorexin A, produced a significant decrease in neurogenic dural vasodilation at the 15-min time point compared with orexin A alone (t₅ = 3.5; P < 0.005; n = 6; Fig. 2) and baseline (F_5,25 = 142.4; P < 0.001; Fig. 2; Table 1). Control vehicle injections demonstrated no significant effect.

View larger version (15K): [in this window] [in a new window]   Fig. 1. Effect of intravenous administration of orexin A (3, 10, and 30 µg kg–1) on neurogenic vasodilation. Following control responses to electrical stimulation, rats were injected with orexin A at 3, 10, or 30 µg kg–1 (n = 6, 6, and 8, respectively) and electrical stimulation was repeated after 5, 15, 30, 45, and 60 min. Only the highest dose of orexin A (30 µg kg–1) inhibits neurogenic dural vasodilation. *, P < 0.05 significance compared with the control response.

View larger version (18K): [in this window] [in a new window]   Fig. 2. Effect of intravenous administration of orexin A (30 µg kg–1) on neurogenic vasodilation and the effect of pretreatment with SB-334867 and coadministration of CGRP8-37. After control responses to electrical stimulation, rats were either injected with orexin A at 30 µgkg–1 (n = 8), orexin A at 30 µgkg–1, and CGRP8-37 at 300 µgkg–1 (n = 6) or pretreated with SB-334867 (n = 6) 5 min before orexin A injection, and electrical stimulation was repeated after 5, 15, 30, 45, and 60 min. Inhibition of neurogenic dural vasodilation is seen in response to orexin A, and this is reversed by the OX1 receptor antagonist SB-334867. CGRP8-37 further inhibits the neurogenic dural vasodilation in the presence of orexin A. *, P < 0.05 significance compared with the control response. #, P < 0.05 significance compared with orexin A inhibition.

Effects of Orexin B on Neurogenic Dural Vasodilation. Orexin B given intravenously at 3 and 10 µg kg^–1 had no effect on neurogenic dural vasodilation (Fig. 3). Orexin B given intravenously at 30 µg kg^–1 elicited a nonsignificant decrease in neurogenic dural vasodilation (F_3.1,18.8 = 0.86; P = 0.48; Fig. 3). Pretreatment with SB-334867 followed 5 min later by 30 µg kg^–1 orexin B elicited a slight increase in neurogenic dural vasodilation; however, this was not significantly different from baseline (F_1.9,9.5 = 1.63; P = 0.26; Fig. 3). Grouped comparisons of orexin B and orexin B post-SB-334867 showed no significant difference between the two treatments. Orexin B administration did not elicit any significant blood pressure changes, and control vehicle injections demonstrated no significant effect.

View larger version (18K): [in this window] [in a new window]   Fig. 3. Effect of orexin B (3, 10, and 30 µg kg–1) on neurogenic vasodilation and the effect of pretreatment with SB-334867 5 min before 30 µg kg–1 orexin B. Following control responses to electrical stimulation, rats were intravenously injected with orexin B at 3, 10, and 30 µg kg–1 (n = 6, 6, and 7, respectively) or pretreated with SB-334867 5 min before 30 µg kg–1 orexin B injection (n = 6), and electrical stimulation was repeated after 5, 15, 30, 45, and 60 min. No significant effect was seen.

Effects of Orexin A on CGRP-Induced Dural Vasodilation. CGRP administration (1 µg kg^–1) produced a reproducible dural blood vessel dilation of 145 ± 7% (n = 6) and a characteristic decrease in blood pressure. Intravenous administration of orexin A at 30 µg kg^–1, which inhibited neurogenic dural vasodilation, had no effect on dural vasodilation in response to CGRP administration (F_5,25 = 0.52; P = 0.75; Fig. 4; Table 3).

View larger version (7K): [in this window] [in a new window]   Fig. 4. Effects of intravenous orexin A (30 µg kg–1) on CGRP (1 µg kg–1)-induced vasodilation. Following control responses to CGRP administration, rats were injected with orexin A at 30 µg kg–1 and CGRP injection was repeated after 5, 15, 30, 45, and 60 min (n = 6). Overall, no significant effect of orexin A on CGRP-induced vasodilation was seen.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
Orexin A was able to significantly inhibit neurogenic dural vasodilation at a dose of 30 µg kg^–1 by a maximum of 60%, and this inhibition was blocked by pretreatment with the selective OX₁ receptor antagonist SB-334867. Together, the data indicate that activation of the OX₁ receptor inhibits neurogenic vasodilation in the dura mater. This effect of orexin A may involve either pre- or postsynaptic receptors, or both, to inhibit dural vasodilation. To examine this further, we have reasoned that exogenous CGRP is acting directly on postsynaptic CGRP receptors in the smooth muscle of dural arteries to induce dural vasodilation. Orexin A is unable to block this effect at concentrations that were able to significantly inhibit neurogenic dural vasodilation, suggesting that the effect of orexin A is presynaptic. The absence of evidence for orexin receptor localization on blood vessels and the absence of both OX₁ and OX₂ receptor mRNA from the heart and aorta (Johren et al., 2001) are in agreement with the current effect being neural. The CGRP receptor antagonist CGRP_8-37, which has been shown to inhibit neurogenic dural vasodilation to 19% when given alone (Williamson et al., 1997a), was able to further inhibit neurogenic dural vasodilation (11%) when administered at the point of maximal inhibition (60%) by orexin A, suggesting that orexin A does not completely block the presynaptic release of CGRP.

Orexin B was unable to significantly alter neurogenic dural vasodilation at all three doses studied. At the 30 µg kg^–1 dose, a nonsignificant trend to a reduction in the dilator response was observed, possibly as a result of an effect at the OX₁ receptor. In the presence of orexin B, pretreatment with the selective OX₁ receptor antagonist SB-334867, although still having no significant effect, caused a slight increase in dural vessel dilation as a result of electrical stimulation. The experimental model used in this study results in dilation of the dural blood vessels under examination, and as such, there is an upper physiological limit to the level of dilation achievable; therefore, one is unable to rule out a possible small effect of orexin B either with or without SB-334867 pretreatment.

The data presented indicate a prejunctional effect for orexin A on the trigeminovascular system, probably from decreased CGRP release. The OX₁ receptor has been identified in the dorsal root ganglion, suggesting its possible presence in the trigeminal ganglion. The exact mechanisms of this inhibitory effect are unknown, because the orexins normally elicit an excitatory response on neurons. It is possible that orexin A is inhibiting the central branch of the trigeminal nerve, in agreement with previous studies demonstrating orexinergic inhibition via spinal orexin receptors (Kajiyama et al., 2005), thus reducing CGRP release from the peripheral end of the trigeminal nerve. This may also explain the lack of effect of orexin B in the current study, because it has been shown to be highly degraded in the blood and crosses the blood-brain barrier poorly (Kastin and Akerstrom, 1999). The possibility of an as yet unknown peripheral effect of OX₁ receptor activation cannot be ruled out (Bingham et al., 2001).

Orexin A injected into the hypothalamus has been shown previously to inhibit significantly cell firing in the trigeminocervical complex in response to dural electrical stimulation and noxious thermal stimulation of the facial skin in the rat (Bartsch et al., 2004). The level of inhibition achieved by intravenous administration of orexin A at a dose of 30 µg kg^–1 in our model of trigeminovascular activation indicates a potent ability to influence the trigeminovascular system directly. As previously reported, the ability to inhibit neurogenic vasodilation has been used to identify potential migraine therapy targets, such as sumatriptan (Williamson et al., 1997b). OX₁ receptor activation causes an inhibition comparable with that of other acute attack treatments, and as such, it may be considered a putative target for migraine medicine development.

The trigeminal ganglion is bipolar, with its afferent fibers innervating the dural blood vessels in the periphery and centrally projecting to the trigeminal nucleus caudalis (TNC). The pharmacology of the peripheral and central branches of the trigeminal ganglion in general matches each other; thus, work demonstrating an effect on the neuronal mechanisms involving the dural blood vessels may also apply to the central neuronal mechanisms in the TNC. A number of compounds, including the triptans, 5-hydroxytryptamine_1B/1D receptor agonists (Williamson et al., 1997c; Boers et al., 2000, 2004), and the CGRP receptor blockers (Williamson et al., 1997a; Storer et al., 2004), are able to inhibit the activation of both the central and peripheral branches of the trigeminal ganglion. Our new data suggest the possibility that OX₁ receptor agonists may be able to inhibit neurons in the TNC directly.

The current study demonstrates that orexin A is able to inhibit neurogenic dural vasodilation via activation of the OX₁ receptor. This effect is most likely prejunctional, acting on the trigeminovascular system and resulting in decreased but not complete blockade of CGRP release. The data complement electrophysiological work in the rat demonstrating that OX₁ receptor activation in the hypothalamus is able to inhibit neuronal firing in the TNC in response to electrical stimulation of the dura mater and noxious thermal stimulation of the facial receptive field (Bartsch et al., 2004). The widespread distribution of the orexins and their receptors throughout the central nervous system, including the hypothalamus, periaqueductal gray, and lamina I, II, and X of the spinal cord (Peyron et al., 1998; Trivedi et al., 1998; van den Pol, 1999), which are all areas involved in nociceptive processing, provides the potential for further research into the role of the orexins in neuronal systems potentially involved in migraine and cluster headache. Orexins may provide some part of the link between some of the remarkable triggering and behavioral manifestations of migraine, such as those involved in feeding, and the disorders of the neuroendocrine and autonomic systems that can be characteristic of the condition.

	Acknowledgements

 
We thank Paul Hammond of the Headache Group at the Institute of Neurology for technical support during these experiments.

	Footnotes

 
The work was supported by the Wellcome Trust.

doi:10.1124/jpet.105.090951.

ABBREVIATIONS: CGRP, calcitonin gene-related peptide; OX₁, orexin 1; SB-334867, N-(2-methyl-6-benzoxazolyl)-N''-1,5-naphthyridin-4-yl urea; TNC, trigeminal nucleus caudalis.

Address correspondence to: Prof. P. J. Goadsby, Institute of Neurology, Queen Square, London WC1N 3BG, UK. E-mail: peterg{at}ion.ucl.ac.uk

	References

Top Abstract Materials and Methods Results Discussion References

 

Akerman S, Williamson DJ, Kaube H, and Goadsby PJ (2002) Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol 137: 62–68.[CrossRef][Medline]

Bartsch T, Levy MJ, Knight YE, and Goadsby PJ (2004) Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 109: 367–378.[CrossRef][Medline]

Bingham S, Davey PT, Babbs AJ, Irving EA, Sammons MJ, Wyles M, Jeffrey P, Cutler L, Riba I, Johns A, et al. (2001) Orexin-A, an hypothalamic peptide with analgesic properties. Pain 92: 81–90.[CrossRef][Medline]

Blanco M, Lopez M, Garcia-Caballero T, Gallego R, Vazquez-Boquete A, Morel G, Senaris R, Casanueva F, Dieguez C, and Beiras A (2001) Cellular localization of orexin receptors in human pituitary. J Clin Endocrinol Metab 86: 3444–3447.[Abstract/Free Full Text]

Boers PM, Donaldson C, Zagami AS, and Lambert GA (2000) 5-HT1A and 5-HT1B/1D receptors are involved in the modulation of the trigeminovascular system of the cat: a microiontophoretic study. Neuropharmacology 39: 1833–1847.[Medline]

Boers PM, Donaldson C, Zagami AS, and Lambert GA (2004) Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy. Cephalalgia 24: 99–109.[Medline]

Cheng JK, Chou RC, Hwang LL, and Chiou LC (2003) Antiallodynic effects of intrathecal orexins in a rat model of postoperative pain. J Pharmacol Exp Ther 307: 1065–1071.[Abstract/Free Full Text]

Cutler DJ, Morris R, Sheridhar V, Wattam TAK, Holmes S, Patel S, Arch JRS, Wilson S, Buckingham RE, Evans ML, et al. (1999) Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord. Peptides 20: 1455–1470.[CrossRef][Medline]

Edvinsson L and Goadsby PJ (1998) Neuropeptides in headache. Eur J Neurol 5: 329–341.

Feindel W, Penfield W, and McNaughton F (1960) The tentorial nerves and localization of intracranial pain in man. Neurology 10: 555–563.

Ferguson AV and Samson WK (2003) The orexin/hypocretin system: a critical regulator of neuroendocrine and autonomic function. Front Neuroendocrinol 24: 141–150.[CrossRef][Medline]

Ferrari MD, Goadsby PJ, Roon KI, and Lipton RB (2002) Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22: 633–658.[CrossRef][Medline]

Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, and Macrae A (2003) Premonitory symptoms in migraine: an electronic diary study. Neurology 60: 935–940.[Abstract/Free Full Text]

Goadsby PJ, Lipton RB, and Ferrari MD (2002) Migraine–current understanding and treatment. N Engl J Med 346: 257–270.[Free Full Text]

Headache Classification Committee of the International Headache Society (2004) The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 (Suppl 1): 9–160.

Johren O, Neidert SJ, Kummer M, Dendorfer A, and Dominiak P (2001) Preproorexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. Endocrinology 142: 3324–3331.[Abstract/Free Full Text]

Kajiyama S, Kawamoto M, Shiraishi S, Gaus S, Matsunaga A, Suyama H, and Yuge O (2005) Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats. Brain Res 1044: 76–86.[Medline]

Kastin AJ and Akerstrom V (1999) Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 289: 219–223.[Abstract/Free Full Text]

Millan MJ, Przewlocki R, Millan MH, and Herz A (1983) Evidence for a role of the ventro-medial posterior hypothalamus in nociceptive processes in the rat. Pharmacol Biochem Behav 18: 901–907.[Medline]

Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, and Lesko LM (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350: 1104–1110.[Abstract/Free Full Text]

Penfield W (1932) Operative treatment of migraine and observations on the mechanism of vascular pain. Trans Am Acad Ophthalmol Otolaryngol III: 1–16.

Penfield W (1934) A contribution to the mechanism of intracranial pain. Proc Assoc Res Nervous Mental Dis 15: 399–415.

Penfield W and McNaughton F (1940) Dural headache and innervation of the dura mater. Arch Neurol Psychiatry 44: 43–75.

Peres MF, Sanchez del Rio M, Seabra ML, Tufik S, Abucham J, Cipolla-Neto J, Silberstein SD, and Zukerman E (2001) Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 71: 747–751.[Abstract/Free Full Text]

Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, and Kilduff TS (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18: 9996–10015.[Abstract/Free Full Text]

Sakurai T (2005) Reverse pharmacology of orexin: from an orphan GPCR to integrative physiology. Regul Pept 126: 3–10.[CrossRef][Medline]

Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92: 573–585.[CrossRef][Medline]

Samson WK, Taylor MM, and Ferguson AV (2005) Non-sleep effects of hypocretin/orexin. Sleep Med Rev 9: 243–252.[CrossRef][Medline]

Siegel JM (2004) Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 55: 125–148.[CrossRef][Medline]

Silberstein SD and de Lignieres B (2000) Migraine, menopause and hormonal replacement therapy. Cephalalgia 20: 214–221.[CrossRef][Medline]

Smart D and Jerman J (2002) The physiology and pharmacology of the orexins. Pharmacol Ther 94: 51–61.[CrossRef][Medline]

Storer RJ, Akerman S, and Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142: 1171–1181.[CrossRef][Medline]

Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, and Guan XM (1998) Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 438: 71–75.[CrossRef][Medline]

van den Pol AN (1999) Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J Neurosci 19: 3171–3182.[Abstract/Free Full Text]

Williamson DJ, Hargreaves RJ, Hill RG, and Shepheard SL (1997a) Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 17: 518–524.[CrossRef][Medline]

Williamson DJ, Hargreaves RJ, Hill RG, and Shepheard SL (1997b) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat-intravital microscope studies. Cephalalgia 17: 525–531.[CrossRef][Medline]

Williamson DJ, Shepheard SL, Hill RG, and Hargreaves RJ (1997c) The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol 328: 61–64.[CrossRef][Medline]

Wolff HG (1948) Headache and Other Headpain, Oxford University Press, New York.

Yamamoto T, Saito O, Shono K, Aoe T, and Chiba T (2003) Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model. Neurosci Lett 347: 183–186.[CrossRef][Medline]

This article has been cited by other articles:

				B. L. Peterlin, G. Alexander, D. Tabby, and E. Reichenberger Oligomerization state-dependent elevations of adiponectin in chronic daily headache Neurology, May 13, 2008; 70(20): 1905 - 1911. [Abstract] [Full Text] [PDF]

				M. E. Bigal, A. Tsang, E. Loder, D. Serrano, M. L. Reed, R. B. Lipton, and for the American Migraine Prevalence and Preventio Body Mass Index and Episodic Headaches: A Population-Based Study Arch Intern Med, October 8, 2007; 167(18): 1964 - 1970. [Abstract] [Full Text] [PDF]

				M. E. Bigal, R. B. Lipton, P. R. Holland, and P. J. Goadsby Obesity, migraine, and chronic migraine: Possible mechanisms of interaction Neurology, May 22, 2007; 68(21): 1851 - 1861. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: jpet.105.090951v1 315/3/1380    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holland, P. R. Articles by Goadsby, P. J. Search for Related Content PubMed PubMed Citation Articles by Holland, P. R. Articles by Goadsby, P. J.